Variability of the thymidine labeling index in squamous cell carcinoma of the head and neck

Greenberg, Bernard R.; Woo, Linda; Blatchford, Steven J.; Aguirre, M.T.; Garewal, Harinder S.

doi:10.1288/00005537-198806000-00018

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a series of 52 oral cavity carcinomas the mean thymidine labelling index was 11%, ranging from 0.01% to 50% (Silvestrini et al, 1984). Greenberg et al (1988) studied seven patients with a squamous carcinoma of the head and neck and found a median thymidine labelling index of 3.7%. They also noted considerable variability in multiple samples of the same tumour, ranging from 0.2 to 23.7%.…”

Section: Statisticsmentioning

confidence: 98%

Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival

Cooke

Cooke²,

Forster³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

Summary Tumour growth rates were measured in 105 patients using in vivo incorporation of bromodeoxyuridine (BrdU) and investigated for any relationship to tumour factors or survival. The median labelling index (LI) was 8.7%, the duration of S-phase (Ts) was 14 h and the potential doubling time (Tpo) was 5.9 days. The labelling index in aneuploid tumours was significantly higher than that in diploid tumours. However the total labelling index (TLI) did not differ significantly between aneuploid and diploid tumours, and so it would seem likely that the difference in LI is due to the dilutional effect of benign tissue upon the calculation of LI in diploid tumours. The total labelling index, duration of S-phase and potential doubling time were not related to the tumour factors examined (site, T The general approach to measuring cell kinetics is to identify a 'window' in the cell cycle and measure the movement of a particular cohort of cells through this window. BrdU, an analogue of thymidine, is incorporated into cells during the S-phase of the cell cycle. BrdU is non-toxic and non-radioactive and can be given intravenously to human patients. Infusions of BrdU at higher dosage can be tolerated for several weeks without severe myelosuppression (Mitchell et al., 1983;Kinsella et al., 1984) and there have been no reports of toxic reactions in any patients receiving BrdU at 200 mg m2. It is taken up by the tumour, and the proportion of cells that have taken up BrdU can be detected using monoclonal antibodies. Furthermore, a pulse label of BrdU can be given approximately 6 h before biopsy or excision of the tumour, allowing the length of S-phase to be calculated (Begg et al., 1985). The simultaneous measurement of BrdU and DNA content using flow cytometry enables several cell kinetic parameters to be quantified. We have previously reported upon the cell kinetic results in 82 tumours and demonstrated their reproducibility (Forster et al., 1992).In this study we present further cell kinetic data on 105 patients with squamous cell tumours of the head and neck and investigate the relationship to tumour stage, site and prognosis.

show abstract

Section: Statisticsmentioning

confidence: 98%

Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival

Cooke

Cooke²,

Forster³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…They were immediately put into transport medium and sent to the laboratory. Greenberg et al [18] observed considerable variability in the labeling index in different sites of the same specimen. They suggested that an average value be determined from multiple sections.…”

Section: Tissue Samplingmentioning

confidence: 99%

Thymidine Labeling Index in Laryngeal Squamous Cell Carcinoma in Correlation with pTNM, Age, Histological Grade and Recurrence

Ünal

Bılır²,

Karatay

2002

ORL

View full text Add to dashboard Cite

In this study, our aim was to investigate the prognostic features of the thymidine labeling index (TLI) in laryngeal squamous cell carcinoma (SCC). The TLI values in tumor tissues and adjacent healthy tissues were assessed in 40 patients who had a pathological diagnosis of laryngeal SCC. The data were correlated with age, pTNM, histological grade and recurrence. The tissues (tumor and adjacent tumor-free tissue) obtained during surgery were labeled with ³H-thymidine. A statistically significant difference was observed between tumoral tissue and adjacent tumor-free tissue (p < 0.05), but we could not confirm any statistically significant correlation between TLI and age, pTNM, histological grade and recurrence. In conclusion, TLI in laryngeal SCC had no significant relation with the clinicopathological features, probably due to the variation in tissue sampling and for tumor-dependent reasons. TLI may assist in differentiating malignant from benign lesions.

show abstract

Measures of tumor proliferative activity

Brooks

1992

Int J Clin Lab Res

View full text Add to dashboard Cite

Tumor proliferative activity, or labeling index, is of interest for gaining insight into the biologic properties of human neoplasm and for providing clinical information that might guide patient management. There has been an abundance of literature reporting experience with standard and newer techniques of measuring tumor proliferative activity. These methods are reviewed with emphasis on technical issues. Particular attention is paid to the development and use of monoclonal antibodies, Ki-67 and anti-PCNA/cyclin. These antibodies are readily available and relatively simple to use. The former has recently been shown to be of prognostic value in non-Hodgkin's large cell lymphomas. A number of studies suggest that indices using these techniques could be useful for a variety of carcinomas, soft tissue tumors, and tumors of the central nervous system.

show abstract

Variability of the thymidine labeling index in squamous cell carcinoma of the head and neck

Cited by 4 publications

References 6 publications

Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival

Prospective evaluation of cell kinetics in head and neck squamous carcinoma: the relationship to tumour factors and survival

Thymidine Labeling Index in Laryngeal Squamous Cell Carcinoma in Correlation with pTNM, Age, Histological Grade and Recurrence

Measures of tumor proliferative activity

Contact Info

Product

Resources

About